John W. Davies
Keine laufenden Positionen mehr
Profil
John W.
Davies worked as the Global Head-Silico Lead Discovery at Novartis Institutes for Biomedical Research, Inc. from 2012 to 2017.
He then worked as the Chief Technology Officer at Kaleido Biosciences, Inc. from 2017 to 2019.
Prior to his professional career, he earned an undergraduate degree from the University of East London and a doctorate from University College London.
Ehemalige bekannte Positionen von John W. Davies
| Unternehmen | Position | Ende |
|---|---|---|
| KALEIDO BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.01.2017 |
Ausbildung von John W. Davies
| University of East London | Undergraduate Degree |
| University College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
